PTEN dysfunction plays a crucial role in the pathogenesis of hereditary and sporadic cancers. Here, we show that PTEN homodimerizes and, in this active conformation, exerts lipid phosphatase activity on PtdIns(3,4,5)P 3 . We demonstrate that catalytically inactive cancer-associated PTEN mutants heterodimerize with wild-type PTEN and constrain its phosphatase activity in a dominant-negative manner. To study the consequences of homo-and heterodimerization of wild-type and mutant PTEN in vivo, we generated Pten knockin mice harboring two cancer-associated PTEN mutations (PtenC124S and PtenG129E). Heterozygous Pten C124S/+ and Pten G129E/+ cells and tissues exhibit increased sensitivity to PI3-K/Akt activation compared to wild-type and Pten +/À counterparts, whereas this difference is no longer apparent between Pten C124S/À and Pten À/À cells. Notably, Pten KI mice are more tumor prone and display features reminiscent of complete Pten loss. Our findings reveal that PTEN loss and PTEN mutations are not synonymous and define a working model for the function and regulation of PTEN.
INTRODUCTION
Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a tumor suppressor frequently lost or mutated in human cancers and in a number of tumor syndromes, referred to as ''PTEN hamartoma tumor syndromes'' (PHTS), which include Cowden disease (CD) and Bannayan-Zonana syndrome (Hollander et al., 2011) .
To study the consequences of Pten loss in vivo, we and others generated animal models with partial and total loss of Pten (Di Cristofano et al., 1998; Podsypanina et al., 1999; Suzuki et al., 1998) . Total Pten loss was found to lead to embryonic lethality, and additional investigations in a hypomorphic allelic series of mice with sequentially lower Pten expression revealed that even small reductions in Pten doses can elicit cancer phenotypes (Alimonti et al., 2010; Trotman et al., 2003) . Conversely, systemic elevation of Pten through transgenic overexpression results in a constitutively augmented tumor-suppressive state (Garcia-Cao et al., 2012) .
PTEN functions as a dual-specificity protein phosphatase (DSP) with predominant enzymatic activity on phosphoinositides (Maehama and Dixon, 1998) . As a phospholipid phosphatase, PTEN catalyzes the hydrolysis of the second messenger PtdIns (3,4,5)P 3 (PIP3) and counteracts the activation of the PI3K/AKT pathway, thus regulating cellular growth, proliferation, and metabolism (Maehama and Dixon, 1998) .
In line with its protein phosphatase function, PTEN has been shown to dephosphorylate phosphopeptides in vitro (Myers et al., 1998) , and reported phosphoprotein targets include the focal adhesion kinase, c-SRC, as well as PTEN itself Tibarewal et al., 2012; Zhang et al., 2011) .
Heterozygous deletion of Pten in mice faithfully phenocopies biological features found in many human tumors with partial loss of PTEN (Di Cristofano et al., 1998) . However, reports indicate that genetic loss of PTEN and mutations leading to PTEN loss of function may not be equivalent. For instance, Marsh et al. (1998) reported a genotype-phenotype correlation in patients diagnosed with CD who developed several tumors, including breast tumors. Importantly, they found that patients harboring missense PTEN mutations in the phosphatase core developed higher numbers of lesions than patients with truncating mutations (Marsh et al., 1998) . This led us to hypothesize that expression of catalytically inactive mutant PTEN enzyme may be more unfavorable than PTEN protein loss.
Regulation of PTEN function occurs through various posttranslational modifications implicated in PTEN membrane recruitment, subcellular localization, or protein-protein interactions (Wang and Jiang, 2008) . Structurally, PTEN belongs to the Class I Cys-based protein tyrosine phosphatase (PTP) and, more specifically, to the VH1-like family (Alonso et al., 2004) . PTEN contains an N-terminal phosphatase domain with a conserved active site; a C-terminal C2 domain followed by two PEST sequences and a PDZ-binding domain (Lee et al., 1999) . It has been reported that PTEN interacts with a number of PDZ-domain bearing proteins to achieve higher levels of complex formation (Sotelo et al., 2012; Vazquez et al., 2001) . We therefore hypothesized, and have here demonstrated, that PTEN can interact with itself. We show that dimer PTEN is active toward its phosphoinositide substrate PIP3 and thereby inhibits the activation of the PI3K/ AKT signaling pathway. Critically, we find that in a dimeric conformation, cancer-associated missense mutations have dominantnegative consequences over wild-type (WT) protein function, with ensuing implications for tumorigenesis.
RESULTS

PTEN Exists in a Dimeric Complex
Given that VH1-like phosphatases are known to exist in higher order complexes/dimers (Koksal and Cingolani, 2011) , we examined whether PTEN could form similar complexes. For this, we performed coimmunoprecipitation (co-IP) experiments using the PTEN null cell line PC3. By cotransfecting differentially tagged PTEN variants we were able to reciprocally co-IP GFPPTEN and MycPTEN ( Figure 1A ). Moreover, in 293T cells overexpressing GFPPTEN, we were able to co-IP endogenous PTEN ( Figure 1B) .
Monomeric PTEN has a molecular weight of 50-55 kDa in denaturing conditions. If a dimeric PTEN existed, it would migrate at double that size in nonreducing and nondenaturing SDS-PAGE. Accordingly, immunoprecipitation (IP) and native elution of MycPTEN from transfected PC3 cells revealed the presence of two bands consistent with the monomeric and dimeric status of the protein (100 kDa circa) (Figure S1A available online). To control for overexpression artifacts, we repeated this assay by pulling down endogenous Pten in NIH 3T3 and confirmed the presence of two bands ( Figure 1C ).
Next, we investigated the contribution of covalent and noncovalent interactions to dimer formation and found that disulfide bonds are not a major requirement for the stabilization of this interaction ( Figure S1B ). We also verified PTEN homodimerization in vitro by coexpressing GST-PTEN and His-PTEN in bacteria. In these experiments, we successfully recovered His-PTEN in GST-PTEN pull-downs ( Figure 1D ).
To further validate the direct binding between PTEN molecules in a eukaryotic system, we employed bioluminescence resonance energy transfer (BRET). To this end, we used Renilla luciferase-PTEN (PTENRluc) as energy donor and GFPPTEN as energy acceptor ( Figure 1E) ; coelenterazine was used as substrate for the luciferase. Coexpression of PTENRluc with GFPPTEN generated a significant increase in the total BRET signal compared to empty GFP, with GFP emission only occurring when in close proximity (<100 Å ) to the luminescent PTENRluc ( Figure 1F ). We also performed competition assays. Coexpression of donor and acceptor proteins with increasing doses of untagged PTEN showed a reduction of net BRET, providing further evidence of direct PTEN-PTEN interaction ( Figure 1G ).
Finally, we sought to determine whether PTEN dimerization occurs in both the nucleus and cytoplasm. Utilizing BRET, we found no variations in nuclear emission over the total BRET signal, neither in basal conditions nor upon serum stimulation, suggesting that PTEN dimer likely exists in both compartments ( Figure 1H ). This finding was confirmed in co-IPs performed upon nuclear versus cytoplasmic fractionation (Figures S1C and S1D) . Thus, we have demonstrated by multiple approaches that PTEN can exist in a homodimeric complex.
PTEN Dimer Is Catalytically Active
To identify the protein domains responsible for PTEN dimer formation, we generated GST-fusion proteins with PTEN N terminus (GST-PTENDC terminus) and PTEN C terminus domains (GST-PTENDN terminus) (Figure 2A ). Coexpression of GST-PTEN full length (FL) with His-PTENFL confirmed the interaction between the two FL proteins ( Figure 2B ). Notably, His-PTENFL was pulled down by both GST-PTEN-domains in bacteria (Figure 2B) . We then tested the binding by co-IPs in PC3 cells and confirmed that in eukaryotic cells PTEN uses multiple interfaces along the entire protein to achieve a dimeric conformation (Figures S2A and S2B) .
To corroborate these findings, we tested the ability of different PTEN domains to homodimerize in vivo ( Figure 2C ). In nonreducing SDS-PAGE, total lysates from PC3 cells transfected with MycPTENFL, MycPTENDN terminus, or MycPTENDPDZ revealed the appearance of upper bands at twice the size of the respective monomeric proteins. Strikingly, upon stabilization of MycPTENDC terminus and MycPTENDCTD with the protease inhibitor MG132, we observed dimeric bands with all PTEN variants tested ( Figure 2D ), with the MycPTENDC terminus showing the highest propensity to self-associate ( Figure 2E) . Notably, the MycPTENDC terminus and MycPTENDN terminus exhibited a potential to oligomerize, as evidenced by additional higher molecular weight bands ( Figure 2D , asterisks).
We also studied binding directionality and found that while in a closed head-to-tail monomeric conformation PTEN is inactive toward its lipid substrate (Leslie and Foti, 2011) , through head-to-head intermolecular binding, it achieves a more active enzymatic conformation ( Figures S2C-S2F) .
We next tested the catalytic activity of antibody-purified PTEN dimers from PC3 cells. PTENFL displayed different affinities toward PTEN deletion mutant versions ( Figure S2B ), and higher levels of dimerization between PTENFL and PTEN domains correlated with higher levels of free phosphate release ( Figure S2E ).
We likewise performed gel filtration of various PTEN species followed by phosphatase assays using PIP3 as substrate. Total lysates of HEK293 cells with exogenous MycPTEN expression were fractioned and a low molecular weight range (30-160 kDa) identified by western blot analysis (Figures 2F, top, and S2G) . Importantly, eluted fractions corresponding to dimeric PTEN (fractions 26-27) generated higher phosphate release than fractions of a lower molecular weight which contained monomeric PTEN (fractions 28-29) ( Figure 2G ). Thus, we conclude that PTEN dimerization defines a more active complex with respect to the less active PTEN monomer.
Phosphorylation of the PTEN Tail
Regulates PTEN Dimerization Next, we studied the conformational status of PTEN by gel filtration analyses. FLAG-tagged PTEN without the C-terminal tail (FlagPTENDCTD) was expressed in HEK293 cells and total lysates were fractioned. Western blot analysis revealed a striking upward shift of tail-less PTEN compared to PTENFL, indicating an enriched dimeric status ( Figure 2F ).
Because the physiologic role of the PTEN tail is mediated by its phosphorylation status (Vazquez et al., 2000) , we performed gel filtration analyses by using phosphomimetic and phosphodead mutant-tail versions of PTEN. We focused specifically on amino acids S380, T382, T383, and S385. By expressing nonphosphorylatable PTEN (PTEN S380A, T382A, T383A, S385A: PTEN4A) we functionally mimicked deletion of the PTEN C-terminal tail. Notably, the PTEN4A presented the same upward shift we found with expression of PTENDCTD ( Figure 2F ). In contrast, expression of a phosphomimetic PTEN (PTEN4E) prevented this shift, indicating a possible role for PTEN tail-phosphorylation in governing its dimeric status ( Figure 2F ). (legend continued on next page) Next, we assessed the phosphorylation level of PTEN dimer. To this end, we immunopurified PTEN and eluted the complex in nonreducing conditions. After tandem-column gel filtrations we analyzed the immunocomplex by reducing and nonreducing SDS-PAGE ( Figure 2H ). In reducing SDS-PAGE, immunopurified PTENFL appeared in two peaks corresponding to a ''low-'' and a ''high-molecular-weight complex'' ( Figure S2H ). We then tested the phospho/nonphospho status of the dimeric PTEN in nonreducing SDS-PAGE. First, with a total PTEN antibody we confirmed the presence of PTEN as a monomer and dimer ( Figure 2I , right). Importantly, we found that while a specific ''phospho-PTEN'' antibody only recognizes the monomeric form, the relative ''nonphospho'' PTEN showed the appearance of both monomeric and dimeric protein ( Figure 2I , left and middle).
Finally, we tested total lysates from HEK293 cells expressing PTEN4A and PTEN4E. Here, we found that while PTEN4E only runs as a single monomeric band ( Figure 2J , bottom), PTEN4A showed monomeric and dimeric PTEN conformations ( Figure 2J , top), in agreement with the shift found by gel filtration. Thus we demonstrate that phosphorylation of the C-terminal tail maintains PTEN as a monomer, whereas the absence of phosphorylation is associated with a dimeric conformation.
PTEN Cancer-Associated Mutations Exert DominantNegative Effects over Wild-Type Protein
We then asked if mutant PTEN protein could form dimers and whether mutations altered dimer formation or activity. The most studied cancer-associated PTEN mutations are the Cys-124 to Ser (C124S) and the Gly-129 to Glu (G129E). C124S mutation generates a catalytically dead PTEN variant that is associated with endometrial cancer and is reported to completely ablate PTEN phosphatase activity (Bonneau and Longy, 2000; Myers et al., 1997) , whereas the G129E mutation is associated with CD and abrogates the phosphoinositide phosphatase function but retains activity toward phosphopeptides (Liaw et al., 1997; Myers et al., 1998) . Both mutations lie in the PTEN catalytic core.
To test our hypothesis, we first analyzed the ability of MycPTENC124S and MycPTENG129E to homodimerize. In nonreducing conditions, we found that both mutants appear as monomers and dimers, like the wild-type protein ( Figure 3A ). PTEN mutants were also able to form heterodimers with wildtype PTEN as found in our co-IP experiments ( Figure 3B ). BRET experiments further demonstrated that PTENWT-Rluc interacted with either GFPPTEN-C124S or G129E ( Figure 3C ).
In bacteria, GST pull-down experiments confirmed that His-PTENWT binds both GST-tagged PTEN mutants ( Figure 3D ). Importantly, purified heterodimers were tested for phosphatase activity on PIP3. In control experiments, GST-PTENWT alone or a His-PTENWT:GST-PTENWT mix produced effective free phosphate release. However, heterodimers comprised of His-PTENWT:GSTPTENC124S or His-PTENWT:GSTPTENG129E had reduced capacity to hydrolyze PIP3 compared to GST-PTENWT ( Figure 3E ), leading us to consider the possibility that in a heterodimeric state, the catalytically inactive mutations inhibited activity of the wild-type PTEN protein toward PIP3, as we next demonstrated in vivo.
Generation and Characterization of Pten Knockin Mutant Mice
To investigate the physiological consequences of PTEN-PTEN mutant heterodimers, we generated mouse models expressing PTENC124S and PTENG129E ( Figures S3A and S3B ). For the Pten C124S/+ and Pten G129E/+ mouse models, we substituted T to A at position 370 or G to A in position 386 of Pten exon5, respectively ( Figure 3F ). In performing the in vivo characterization of these new Pten KI mice, we also aimed to investigate two critical aspects of PTEN regulation: stability and localization. First, since many PTEN missense point mutations render PTEN unstable , we measured the mutant Pten proteins levels in our Pten KI mice. We observed that Pten C124S/+ and Pten G129E/+ express a total level of Pten that is comparable to levels in Pten wild-type mice ( Figure 3G ). Second, to exclude the contribution of defective cellular distribution to our analysis, we performed cell-fractionation and immunofluorescence (IF) (legend continued on next page) Pten G129E/+ mice developed lymphoproliferation features by 16 weeks ( Figure S3E ). Accordingly, older Pten KI mice had increased spleen weights, compared to Pten +/À mice, owing to severe extramedullary hematopoiesis and lymphoid hyperplasia; we also found extended expansion of white blood cells in the peripheral blood ( Figure S3F ). In solid tissues, the tumor spectrum of Pten KI mice was indistinguishable from Pten +/À mice, with lesions developing in several glands and organs ( Figures  S3C and S3D) Figures 4C and S4C ).
As PTEN loss also leads to defects in neuronal development, we assessed the status of different neuronal populations (Fraser et al., 2004) . Histopathological analysis revealed that only the pituitary gland presented signs of tumorigenesis, with adenomas developing primarily in the anterior lobe ( Figure S4E ) (Bai et al., 2006) . However, in the cerebellum, we found that while Pten +/À mice had histologically normal brains, both Pten KI cohorts developed features of Lhermitte-Duclos disease, or ''dysplastic gangliocytoma'' ( Figures 4D, 4E, S4D , and S4G) (Backman et al., 2001; Kwon et al., 2001 ). An average of 25% of Pten C124S/+ and Pten G129E/+ mice had enlarged areas in the cerebellum, with disorganized spreading of granule cells into the molecular layer, increased thickness of the molecular layer itself, and the presence of neurons expressing the neuronal marker, NeuN ( Figure 4F ). Immunostaining confirmed the expansion of glial cells (mostly astrocytes, GFAP positive, Figure 4F ), together with an increased number and size of glial fibers, as shown by positivity to the proliferation marker PCNA ( Figure S4F ). Affected areas reshaped the structure of the cerebellar lobes and led to dispersion of the Purkinje cells in the molecular layer (Calbindin staining in Figure 4F ). These ''PHTS'' features were found as early as 4 months of age and presented in small localized areas, as well as in more developed lesions that pervaded the whole cerebellum ( Figure 4E) . Notably, conditional loss of Pten in the brain, under Gfap-driven Cre expression, leads to similar findings (Backman et al., 2001; Kwon et al., 2001 (Figures 5A and 5B ). We next examined Akt phosphorylation in preonset mammary glands of 10-to 12-week-old mice by immunohistochemical staining (IHC) and found that Pten KI mice presented the strongest signal (Figure 5C ), which persisted in tumor lesions of older mice ( Figures  S3G and S4C ).
To further test the propensity of Pten mutations to induce Akt hyperactivation, we generated mouse embryonic fibroblasts (MEFs). Insulin-like growth factor (IGF) stimulation led to acute Akt phosphorylation in Pten-KI-derived MEFs, again much higher than in Pten +/À cells ( Figure 5D ). Similar results were observed upon insulin stimulation ( Figure S5A ). In addition, by monitoring the activation profile over time, we found that after 1 hr of insulin stimulation, Pten KI MEFs sustained higher levels of phospho-Akt ( Figure 5E ). We next examined cellular levels of PIP3, which is mainly found on the leading edges of filopodia and lamellipodia, to stimulate cell migration and invasion (Kö lsch et al., 2008) . In MEFs, IF experiments showed that 1 min of insulin stimulation led to PIP3 accumulation at the membrane of all samples, with Pten KI MEFs showing the strongest signal ( Figure 5F ).
(E) Fractions of PTEN dimers purified as in (D), plus GST-PTENWT alone were purified. Catalytic activity of PTEN dimers was tested in phosphatase assays using PIP3 as substrate. PO4 released is normalized over levels of His-PTEN pulled down and is shown relative to the PO4 released by GST-PTENWT alone. Mean values of triplicate wells with associated SD are shown. (legend continued on next page)
Next, we monitored activation levels of Akt isoforms. Out of the three, Akt1 and Akt2 are more widely expressed, and their contributions to tumorigenesis have been better characterized (Gonzalez and McGraw, 2009 ). Thus, we performed IP-western blot analysis on Akt1 and Akt2 and found that both proteins were hyperphosphorylated in Pten KI MEFs (Figures S5C and S5D) . We also examined expression levels of key components of the PI3K pathway and found no changes in total levels of its upstream or downstream components ( Figure 5G) ; nor did we find alteration in the formation of the PI3K complex (p85:p110 binding) across the Pten genotypes ( Figure S5B ).
We then monitored the activation of several Akt targets, including the mTORC1 complex. We found that upon insulin stimulation, Pten KI MEFs displayed increased levels of PRAS40 phosphorylation compared to Pten +/À cells, resulting in mTORC1
activation and faster accumulation of phospho-S6, its downstream substrate ( Figures 5H, S5F , and S5G). Pten KI MEFs also displayed reduced levels of IRS1, probably due to negative feedback loops driven by mTORC1activation ( Figure 5G ) (Shah et al., 2004) . We also monitored activation of Akt targets including TSC2, Foxo1, and Foxo3a, but while both Foxo proteins were more phosphorylated in Pten KI MEFs compared to Pten +/À , the status of phospho TSC2 remained unchanged ( Figure 5H ).
Finally, we tested the status of proposed Pten protein substrates and established their potential contribution to Pten loss driven tumorigenesis. Zhang et al., 2011) . In our experimental conditions, however, while IGF stimulation led to Akt hyperactivation, the phosphorylation status of Fak and Src were not significantly affected across the Pten genotypes ( Figure S5E ). G129E/+ MEFs and tested the respective phosphatase activity toward PIP3. We found that free phosphate production by the heterodimeric complexes was lower than that found under Pten heterozygous conditions. Accordingly, reduced PIP3 hydrolysis led to increased Akt phosphorylation ( Figures  6A and 6B ). Because PIP3 is produced in the inner leaflet of the plasma membrane, we next analyzed Pten membrane recruitment. To this end, we coexpressed GFPPTEN WT or mutants alongside untagged PTENWT in PC3 cells and monitored the ability of the different GFPPTEN species to localize to the plasma-membrane (PM) ( Figure S6A ). We found that, upon starvation and serum stimulation, GFPPTEN mutant proteins showed a 12% greater concentration (on average) at the membrane than GFPPTEN WT ( Figure S6B ).
Dimerization and Membrane
To verify that PTEN is present at the membrane as homoor heterodimers, we repeated this assay by coexpressing GFPPTEN variants with mCherry-tagged PTENWT. Coexpression of mCherryPTENWT with GFPPTENWT displayed a linear accumulation of GFP and mCherry signals at the PM, with <2% intrinsic variation, likely due to different backbone plasmids. However, in coexpressing C124S or G129E-GFP variants with mCherry-PTENWT, we observed that the GFP detection at the PM was only 4% more intense than the mCherry signal (Figures 6C and S6C ), suggesting that, although both mutants are recruited to the membrane more rapidly than PTEN WT, they are also able to promote enhanced mCherry-PTENWT membrane recruitment through dimerization.
In addition, co-IPs from PC3 cell-membrane fractions confirmed that MycPTENWT can bind GFPPTENWT and GFPPTEN mutants at the membrane ( Figure 6D ). Thus we propose that ''inactive'' hetero-and homodimers may displace and outcompete the function of ''active'' PTEN WT homodimers.
Consequence of PTEN Mutations on Loss of Heterozygosity and Akt Activation in Mouse Models and Humans
In the mouse, monoallelic loss of Pten leads to tumor initiation while cancer progression often selects for loss of the functional Pten allele (Hollander et al., 2011) . Thus, we asked whether in Pten KI mice, the dominant-negative action of mutant over wild-type Pten protein would trigger advanced tumorigenesis also in the absence of loss of heterozygosity (LOH). We therefore performed Southern blot (SB) analysis and laser capture microdissection (LCM) on large breast adenocarcinoma samples from Pten KI mice. By SB we found that on average, 50% of the Pten KI breast samples fully retained the Pten wt allele ( Figure S6D ). To test a larger number of samples, we then performed LCM and PCR amplification on DNA extracts and found mixed genomic profiles with only one out of six Pten C124S/+ samples (16%) displaying total LOH and two out of six Pten G129E/+ samples (33%) presenting either partial or total LOH ( Figure 6E ).
Next, we examined the status of the Pten protein by IHC and found predominantly positive staining, with areas of reduced intensity in agreement with the percentage of LOH found by SB and LCM ( Figure 6F ). This finding argues that the dominantnegative effect of Pten mutations exerts their negative protumorigenic effects even in the absence of LOH; however, when cancer arises, intratumoral variability and accumulation of additional mutations will eventually favor focal loss of Pten. Thus the persistent Akt hyperactivation, as found in large adenocarcinomas ( Figure S6E ), leads to accelerated cancer formation, while PTEN LOH, when observed, may further favor tumor progression. To assess whether our observations were consistent with the molecular changes occurring in human tumorigenesis, we examined the association between PTEN mutational status and AKT activation in human cancers. For this, we analyzed data sets from The Cancer Genome Atlas available at the cBio portal (http://www.cbioportal.org) and matched the genetic status of PTEN with the reverse-phase protein arrays (RPPA) data for AKT. We found that samples with heterozygous mutations in PTEN (and no copy number alteration, including two PTENG129E mutant cases) were associated with higher levels of AKT phosphorylation (on both Thr308 and Ser473) compared to samples with heterozygous PTEN loss (and no additional mutations) ( Figure 6G ), independent of total Akt levels ( Figure S6F ). These data support the notion that PTEN mutations have greater consequence than heterozygous PTEN loss in promoting PI-3K/ AKT hyperactivation and may predict for higher sensitivity to AKT inhibition in human cancers. Unfortunately, this could not be addressed in MEFs because complete Pten loss is known to trigger cellular senescence in these cells (Chen et al., 2005) ; indeed, we found that Pten C124S/+ MEFs presented increased senescence over Pten
MEFs upon passaging ( Figures S6G-S6I ). To overcome this problem, we made use of a conditional knockout strategy induced by the CD4-Cre recombinase, which is active in the double-positive lymphocyte stage of thymus development (Figure 6H ). Extracted thymocytes were cultured and their PI3K-signaling output analyzed by western blot and flow cytometry analysis, respectively. Critically, in this setting we found no consistent differences in signaling output across the genotypes ( Figures 6I and 6J) , further supporting a model in which Pten mutations enhance PI3K/Akt oncogenic signaling by inhibiting its WT counterpart.
Functional Evaluation of PTENR130G Mutation
Because PTENC124S and PTENG129E mutations are only found in a subset of cancer and genetic syndromes, we next tested the functional role of three additional PTEN mutations more commonly found in human disease: PTENR130G, PTENR130X, and PTENR233X (Bonneau and Longy, 2000) . PTENR130X and R233X nonsense mutations introduce stop codons that generate very unstable PTEN proteins that are almost undetectable ( Figure S7A ) and thus are functionally comparable to the PTEN heterozygous condition. The PTENR130G missense mutation, however, generates a stable protein that suffers loss of its lipid phosphatase function (Kato et al., 2000) . In this respect, PTENR130G phenocopies PTENC124S and PTENG129E, so we further investigated its potential dominant-negative effect. First, we confirmed that this mutation has no suppressive effect on phospho-AKT levels in PTEN null cells ( Figure 7A ). We next determined that PTENR130G can interact with WT PTEN in bacteria as well as eukaryotic cells (Figures 7B and  7C) . Then, by testing the phosphatase function of HisPTENWT-GSTPTENR130G heterodimer purified from bacteria, we found that when bound together, PTENR130G limits the function of the WT protein to inhibit PIP3 dephosphorylation ( Figure 7D ). In addition, overexpression of PTEN mutations in PTEN-competent 293T cells displayed increased phospho-AKT on T308 than cells expressing empty vector, overcoming the function of endogenous PTEN ( Figure 7E ).
Finally, we found that samples harboring mutations on PTENR130 either mutated to Gly (R130G) or to Gln (R130Q) in a total of 19 samples from glioblastoma and endometrial cancers exhibited higher levels of AKT phosphorylation than samples with monoallelic loss of PTEN ( Figure 7F ).
DISCUSSION
In this study, we have demonstrated that PTEN dimerization is critical for its lipid phosphatase function. We have also proposed that dimeric PTEN complexes are more active than PTEN monomer in dephosphorylating PIP3 and regulating PI3K signaling. By studying two PTEN cancer-associated mutations, we revealed that while disrupting PTEN activity in cis, PTENC124S and PTENG129E inhibit the WT protein function in trans in a dominant-negative manner as a result of heterodimerization. In turn, this reduced Pten lipid-phosphatase activity leads to Akt hyperactivation and increased tumorigenesis in the mouse.
These findings allow us to reach several conclusions. Mechanistically, we have defined that PTEN exists as a dimer. Given that PTEN is part of the VH1-like family of DSPs, it is relevant that the prototypical VH1 phosphatase is known to exist in a dimeric-quaternary complex whose assembly is essential for the recognition of its substrate, STAT1 (Koksal and Cingolani, 2011) . Moreover, phosphorylation of the PTEN tail is known to produce an inactive form of the enzyme in a closed conformation (Leslie and Foti, 2011) . In agreement, we provide evidence that dephosphorylation of the PTEN-tail, while favoring a more open conformation, also allows subsequent dimerization and, possibly, oligomerization, in view of the multiple interfaces found to mediate the PTEN-PTEN interaction.
The role of PTEN dimerization in cancer is particularly important when we consider the high frequency of PTEN mutations in sporadic tumors and inherited syndromes. In this study, we have analyzed in vivo and in vitro two cancer-and CD-associated missense mutations and extended our analysis to a third mutation, PTENR130G. In the future, it will be important to study various PTEN mutations in a systematic manner. It is tempting to speculate that other PTEN mutants may affect the function of the PTEN WT protein through physical interactions and perhaps at multiple levels, e.g., by affecting PTEN extracellular export (Hopkins et al., 2013; Putz et al., 2012) . Clinically, our study implies that patients harboring these, or similar loss-of-function missense mutations, may be more susceptible to malignant cancer and may develop it more rapidly than patients expressing reduced levels of PTEN or expressing PTEN-destabilizing mutations. Thus we propose that PTEN mutational status may be utilized to stratify patients who may benefit from earlier and more radical therapeutic intervention modalities, potentially leading to improved prognoses.
Although we cannot exclude the possibility that certain PTEN mutations may become competent toward targets not recognized by the wild-type protein in a ''gain-of-function'' scenario (Wang et al., 2010) , our genetic analyses support a model in which the ability of mutant PTEN to interfere with WT protein function contributes to exacerbation of tumor spectrum compared to Pten heterozygosity ( Figure 7G ). While these mutations induce acceleration of tumorigenesis, they specifically act by further lowering Pten activity rather than engaging alternative pathways. Accordingly, we found that Pten KI mice developed Lhermitte-Duclos disease, as previously reported in mice with total conditional Pten loss, while lesions of different histological origins not associated with Pten loss (such as sarcomas) were not observed.
Additionally, in monitoring the activation status of proposed PTEN phosphoprotein targets we found no obvious changes upon IGF stimulation, or variation between tumor spectra of the two Pten KI models. This implies that even if cancer-relevant PTEN phosphoprotein targets are present and deregulated in Pten C124S/+ mice, concomitant Akt hyperactivation may overcome their effects, perhaps due to increased cellular senescence ( Figure S6G ). While several reports have highlighted the possibility that PTEN protein phosphatase activity may be related to regulation of migration and invasion (Tibarewal et al., 2012) , in our in vivo analysis of the Pten KI mice we did not observe metastasis. However, the general exacerbation of solid tumorigenesis in multiple organs and pronounced lymphoproliferation may have masked a possible metastatic phenotype in elder mutants. In summary, we have identified features of PTEN biology through the characterization of cancer-associated PTEN missense mutations. Given the ongoing development of agents targeting the PI3K pathway including AKT-inhibitors, our findings may help to identify patients that may be sensitive to these agents due to high levels of AKT activation associated with a PTEN mutant state.
EXPERIMENTAL PROCEDURES
Western Blotting, Immunoprecipitation, and In Vitro Binding For details on western blotting, immunoprecipitation, and in vitro binding please refer to Extended Experimental Procedures.
Gel Filtration Chromatography
For gel filtration experiments please refer to Extended Experimental Procedures.
Mice and Immunohistochemistry
Autopsy and histological analysis was performed on cohorts of female and male mice from 2-13 months of age. Mouse tissues were fixed in 4% PFA. Normal and tumor tissues were embedded in paraffin, sectioned, and hematoxylin and eosin (H&E) stained for pathological evaluation. Brain tissues were fixed in Bouin's solution. Please refer to Extended Experimental Procedures for details on the generation of mouse lines. All mice were cared for according to NIH-approved institutional animal care guidelines and studies approved by the Institutional Committee at the Beth-Israel Deaconess Medical Center.
Studies with Primary Cells
Mouse embryonic fibroblasts (MEFs) were isolated at day E13.5 and maintained in culture as described (Todaro and Green, 1963) . MEFs between passages 1 and 3 were used for all experiments. Senescence assays were performed as described (Chen et al., 2005) .
Isolation of primary mammary epithelial cells (MECs) was performed as previously described (Song et al., 2013) . Please refer to Extended Experimental Procedures for details.
PtdIns(3,4,5)P 3 Phosphatase Assay PC3 cells and primary MEFs lysates from Pten lines were IP and subjected to native elution. For phosphatase assays, a solution with 25 mM Tris-HCl (pH 7.5), 140 mM NaCl, 1 mM DTT, and 100 mM diC 8 -PtdIns(3,4,5)P 3 (Echelon) was prepared and assay ran at 37 C for 45 min. Free phosphate release was measured with Green Reagent (Biomol) and according to the manufacturer's instructions.
Population BRET Imaging PC3 cells seeded on 35 mm wells were transfected with indicated expression vectors. After 48 hr, cells were scraped and transferred into a white OptiPlate-96 (Perkin Elmer). Luminescent emission was stimulated by adding 5 mM Coelenterazine and signal collected with the Victor3 plate reader (Perkin Elmer). Please refer to Extended Experimental Procedures for details.
Bioinformatic Analysis
We used tissue samples from The Cancer Genome Atlas (TCGA) project to assess relationships between PTEN mutation status, PTEN copy number status, and expression levels of AKT and pAKT in human cancer samples. Please refer to Extended Experimental Procedures for details.
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